Survival and Clinical Outcomes with Telotristat Ethyl in Patients with Carcinoid Syndrome

PURPOSE: The TELEACE study showed reductions in tumor size in patients with neuroendocrine tumors, receiving telotristat ethyl in US clinical practice. Here, we report progression-free survival, time to tumor progression, changes in carcinoid syndrome symptoms, and indictors of overall health. PATIE...

Descripción completa

Detalles Bibliográficos
Autores principales: Metz, David C, Liu, Eric, Joish, Vijay N, Huynh, Lynn, Totev, Todor I, Duh, Mei Sheng, Seth, Kiernan, Giacalone, Susan, Lapuerta, Pablo, Morse, Michael A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7548219/
https://www.ncbi.nlm.nih.gov/pubmed/33116830
http://dx.doi.org/10.2147/CMAR.S276519

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7548219/
https://www.ncbi.nlm.nih.gov/pubmed/33116830
http://dx.doi.org/10.2147/CMAR.S276519

Ejemplares similares